Dr Agarwals Health Care Ltd

- There is a Rs. 70 crore preferential allotment by AHCL to AEHL at Rs. 5,270 per share to finance immediate fund requirements for CAPEX, specifically for the flagship facility at Cathedral Road. - This preferential allotment is equity-based and not subject to merger completion; it will be completed ahead of the merger. - No specific mention of additional future fundraising through debt or further equity was made in the transcript. - The management prefers equity infusion (preferential allotment) over increasing debt for funding subsidiary’s growth. - The merger aims to strengthen the balance sheet and provide a larger cash pool for expansion and growth post-merger. - No explicit plan for additional debt issuance was discussed during the call.

- AHCL plans a capital expenditure (CAPEX) for the construction of the flagship facility at Cathedral Road. - A preferential allotment of approximately Rs. 70 crores from AHCL to AEHL will finance immediate fund requirements related to this CAPEX plan. - Post allotment, AEHL's share capital will increase, with promoter holding rising slightly. - The infusion aims to support AEHL's growth and expansion initiatives. - The merger will enable unified capital allocation and strengthen the balance sheet, supporting future growth. - Post-merger, combined resources and consolidated cash pools will be strategically deployed for growth and operations. - The merger intends to provide better utilization of combined business resources and access to larger clinical talent.

Future growth expectations highlighted in the transcript include: - Post-merger, AEHL shareholders will benefit from participation in AHCL's high-growth pan India story, suggesting anticipated expansion beyond current geographies. - Access to larger clinical talent pool and consolidated cash resources is expected to support expansion and efficient capital allocation. - Investment of Rs. 70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service enhancement. - Synergies from merger anticipated to improve operational efficiencies, reduce compliance and taxation costs, optimizing resource utilization. - Combined entity expected to accelerate growth through unified operations and a simplified corporate structure. - Stakeholders view the merger as unlocking the next phase of growth, indicating positive outlook on revenue, volume, and geographic expansion. Overall, the strategic merger aims to drive sustainable revenue growth by leveraging scale, operational efficiencies, and enhanced market presence.

- The merger aims to create a simplified and more efficient group structure enabling faster decision-making and unified capital allocation. - Combined entity provides access to larger cash resources for strategic deployment supporting expansion and growth. - AEHL shareholders gain participation in AHCL’s pan-India high-growth story with a larger clinical talent pool. - Synergies from merger expected to reduce compliance costs, tax leakage, and optimize resource utilization, potentially improving EBITDA margins. - Larger consolidated operations and market presence expected to drive long-term value creation and growth opportunities. - Although specific future earnings or EPS guidance isn’t detailed, management emphasizes the merger will unlock the "next phase" of the growth journey benefiting shareholders. - Minority shareholders will now participate in a larger, faster-growing entity with enhanced operational and financial efficiencies.

The provided transcript from Dr. Agarwal’s Health Care Limited's analyst call dated August 28, 2025, does not contain specific information on current or expected order book or pending orders. The discussion primarily focuses on the proposed merger between Dr. Agarwal's Eye Hospital Limited (AEHL) and Dr. Agarwal's Health Care Limited (AHCL), valuation concerns, shareholder approvals required, and corporate governance issues. There is no mention of order book status or pending orders in the call transcript or the related presentation excerpts. If you need detailed information on current or expected orders, it may be available in other company disclosures or quarterly earnings reports not included in this document.